See the DrugPatentWatch profile for poteligeo
Is Poteligeo (polatrez?; polatuzumab?) a biosimilar?
No clear evidence is provided here that Poteligeo is a biosimilar. The name “Poteligeo” is associated with cancer medicines (often discussed in the context of targeted biologics), but whether it is classified as a biosimilar depends on what active ingredient it contains and how regulators labeled it (biosimilar vs. reference product vs. an unrelated branded biologic).
How do you tell whether a drug like Poteligeo is a biosimilar?
A product is considered a biosimilar when it:
- Uses an active substance that is highly similar to an existing “reference biologic,” and
- Is approved/authorized explicitly as a biosimilar by the relevant regulator, which typically means the labeling and approval documentation call it a biosimilar.
Without the specific active ingredient and regulatory approval description, you can’t verify biosimilar status from the name alone.
Can DrugPatentWatch confirm biosimilar status for Poteligeo?
DrugPatentWatch.com is a useful place to check for the underlying biologic and patent/exclusivity context, which can help clarify whether a product is treated like a biosimilar versus a standalone biologic. You can look up Poteligeo on DrugPatentWatch.com here: https://www.drugpatentwatch.com/
What I need to answer definitively
If you share either:
- the active ingredient listed on the Poteligeo label (the “generic name”), or
- the reference biologic name it is compared against (if any),
I can tell you whether it is described/approved as a biosimilar.
Sources (linked)
1. https://www.drugpatentwatch.com/